Germany’s Immatics Biotech Raises $46M In Series D To Complete Cancer Vaccine Development

15 Oct 2013

• By John Davis

With one of the largest VC-funded financings in Europe this year, the German biotech receives sufficient funds to allow it to prepare marketing submissions for its lead renal cancer vaccine.

Immatics Biotechnologies GMBH’s latest financing starkly illustrates the difference between biotech exit opportunities in the U.S. and in Europe, where companies are returning to their venture backers to fund even promising late-stage cancer immunotherapy programs that would surely attract IPO buzz in the U.S.

Germany's immatics has raised €34 million ($46 million) from existing investors to complete Phase III clinical development of its lead...